Osteopore Secures AUD 520,000 Upfront Fee in Majeton China Collaboration

Osteopore Ltd. ( (AU:OSX) ) has issued an announcement.

Osteopore Ltd. has received an upfront dossier fee of RMB 2.5 million (about AUD 520,000) from its partner Majeton under their exclusive collaboration to commercialise Osteopore’s dental, orthodontic and maxillofacial products in China, Hong Kong and Macau. The payment marks early progress in Osteopore’s push into Greater China, with the partners now working toward product listing and regulatory milestones across those markets, scheduled over timelines running from mid-2027 to early 2034, which could significantly expand Osteopore’s regional presence if achieved.

The most recent analyst rating on (AU:OSX) stock is a Sell with a A$0.01 price target. To see the full list of analyst forecasts on Osteopore Ltd. stock, see the AU:OSX Stock Forecast page.

More about Osteopore Ltd.

Osteopore Ltd. is an Australian-Singaporean medical technology company that develops and commercialises 3D-printed biomimetic and bioresorbable implants designed to enable natural bone healing across multiple therapeutic areas. Its patented scaffold technology uses a proprietary polymer that dissolves over time, leaving regenerated bone and aiming to reduce complications associated with permanent implants.

Average Trading Volume: 31,878,288

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$4.5M

See more insights into OSX stock on TipRanks’ Stock Analysis page.